Annual EBIT
-$27.14 M
+$24.05 M+46.98%
December 31, 2023
Summary
- As of February 12, 2025, QNCX annual earnings before interest & taxes is -$27.14 million, with the most recent change of +$24.05 million (+46.98%) on December 31, 2023.
- During the last 3 years, QNCX annual EBIT has risen by +$51.75 million (+65.60%).
- QNCX annual EBIT is now -156.25% below its all-time high of -$10.59 million, reached on December 31, 2017.
Performance
QNCX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$8.55 M
+$296.00 K+3.35%
September 30, 2024
Summary
- As of February 12, 2025, QNCX quarterly earnings before interest & taxes is -$8.55 million, with the most recent change of +$296.00 thousand (+3.35%) on September 30, 2024.
- Over the past year, QNCX quarterly EBIT has dropped by -$203.00 thousand (-2.43%).
- QNCX quarterly EBIT is now -238.99% below its all-time high of -$2.52 million, reached on September 30, 2018.
Performance
QNCX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$34.40 M
-$2.45 M-7.67%
September 30, 2024
Summary
- As of February 12, 2025, QNCX TTM earnings before interest & taxes is -$34.40 million, with the most recent change of -$2.45 million (-7.67%) on September 30, 2024.
- Over the past year, QNCX TTM EBIT has dropped by -$7.33 million (-27.06%).
- QNCX TTM EBIT is now -1138.44% below its all-time high of -$2.78 million, reached on March 31, 2018.
Performance
QNCX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
QNCX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.0% | -2.4% | -27.1% |
| 3 y3 years | +65.6% | -2.4% | -27.1% |
| 5 y5 years | -135.6% | -2.4% | -27.1% |
QNCX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +70.0% | -53.0% | +63.7% | -37.3% | +61.9% |
| 5 y | 5-year | at high | +70.0% | -53.0% | +63.7% | -37.3% | +61.9% |
| alltime | all time | -156.3% | +70.0% | -239.0% | +63.7% | -1138.4% | +61.9% |
Quince Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.55 M(-3.3%) | -$34.40 M(+7.7%) |
| Jun 2024 | - | -$8.84 M(+1.9%) | -$31.95 M(+11.4%) |
| Mar 2024 | - | -$8.67 M(+4.0%) | -$28.69 M(+6.0%) |
| Dec 2023 | -$27.14 M(-47.0%) | -$8.34 M(+36.9%) | -$27.08 M(+8.1%) |
| Sep 2023 | - | -$6.09 M(+9.1%) | -$25.05 M(-2.7%) |
| Jun 2023 | - | -$5.58 M(-20.9%) | -$25.75 M(-29.3%) |
| Mar 2023 | - | -$7.06 M(+11.7%) | -$36.43 M(-28.9%) |
| Dec 2022 | -$51.19 M(-43.3%) | -$6.32 M(-7.0%) | -$51.23 M(-25.2%) |
| Sep 2022 | - | -$6.79 M(-58.2%) | -$68.46 M(-17.9%) |
| Jun 2022 | - | -$16.26 M(-25.6%) | -$83.34 M(-6.2%) |
| Mar 2022 | - | -$21.86 M(-7.1%) | -$88.87 M(-1.6%) |
| Dec 2021 | -$90.32 M | -$23.54 M(+8.6%) | -$90.32 M(+3.1%) |
| Sep 2021 | - | -$21.68 M(-0.5%) | -$87.63 M(-0.3%) |
| Jun 2021 | - | -$21.78 M(-6.6%) | -$87.86 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$23.31 M(+11.8%) | -$84.35 M(+6.9%) |
| Dec 2020 | -$78.89 M(+101.4%) | -$20.85 M(-4.8%) | -$78.89 M(+11.1%) |
| Sep 2020 | - | -$21.91 M(+19.9%) | -$70.99 M(+19.0%) |
| Jun 2020 | - | -$18.27 M(+2.3%) | -$59.65 M(+17.1%) |
| Mar 2020 | - | -$17.86 M(+37.9%) | -$50.95 M(+30.1%) |
| Dec 2019 | -$39.17 M(+240.0%) | -$12.95 M(+22.5%) | -$39.17 M(+31.9%) |
| Sep 2019 | - | -$10.57 M(+10.4%) | -$29.69 M(+37.2%) |
| Jun 2019 | - | -$9.57 M(+57.6%) | -$21.64 M(+46.1%) |
| Mar 2019 | - | -$6.08 M(+75.1%) | -$14.82 M(+28.6%) |
| Dec 2018 | -$11.52 M(+8.8%) | -$3.47 M(+37.6%) | -$11.52 M(+43.1%) |
| Sep 2018 | - | -$2.52 M(-8.3%) | -$8.05 M(+45.6%) |
| Jun 2018 | - | -$2.75 M(-1.0%) | -$5.53 M(+99.0%) |
| Mar 2018 | - | -$2.78 M | -$2.78 M |
| Dec 2017 | -$10.59 M | - | - |
FAQ
- What is Quince Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Quince Therapeutics?
- What is Quince Therapeutics annual EBIT year-on-year change?
- What is Quince Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Quince Therapeutics?
- What is Quince Therapeutics quarterly EBIT year-on-year change?
- What is Quince Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Quince Therapeutics?
- What is Quince Therapeutics TTM EBIT year-on-year change?
What is Quince Therapeutics annual earnings before interest & taxes?
The current annual EBIT of QNCX is -$27.14 M
What is the all time high annual EBIT for Quince Therapeutics?
Quince Therapeutics all-time high annual earnings before interest & taxes is -$10.59 M
What is Quince Therapeutics annual EBIT year-on-year change?
Over the past year, QNCX annual earnings before interest & taxes has changed by +$24.05 M (+46.98%)
What is Quince Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of QNCX is -$8.55 M
What is the all time high quarterly EBIT for Quince Therapeutics?
Quince Therapeutics all-time high quarterly earnings before interest & taxes is -$2.52 M
What is Quince Therapeutics quarterly EBIT year-on-year change?
Over the past year, QNCX quarterly earnings before interest & taxes has changed by -$203.00 K (-2.43%)
What is Quince Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of QNCX is -$34.40 M
What is the all time high TTM EBIT for Quince Therapeutics?
Quince Therapeutics all-time high TTM earnings before interest & taxes is -$2.78 M
What is Quince Therapeutics TTM EBIT year-on-year change?
Over the past year, QNCX TTM earnings before interest & taxes has changed by -$7.33 M (-27.06%)